Tango Therapeutics Inc. TNGX · Stock Open Tango Therapeutics Inc. in new tab
Tango Therapeutics Inc. Analysis (TNGX)
Is Tango Therapeutics Inc. a good investment? Tango Therapeutics Inc. (TNGX) is currently trading at 27.21 USD. Market analysts have a consensus price target of 44.33 USD. This suggests a potential upside from current levels.
Earnings Schedule: Tango Therapeutics Inc. is expected to release its next earnings report on Aug. 4, 2026. The market consensus estimate for Forward EPS is -1.52.
Investor FAQ
Does Tango Therapeutics Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Tango Therapeutics Inc.?
Tango Therapeutics Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 4, 2026. The company currently has a trailing EPS of -0.83.
Company Profile
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Community Discussion